Biotech Values

[flatlander_60048]

I'd caution that PFE will likely face stiff competition for Spiriva in the coming months. NVS has launched onbrez in many European markets and filed for approval in the US in late Sept. Since the filing provides the testing results that address the FDA issues from 2009 Approvable letter, I think it is highly likely to gain approval.

I'm long NVS. However, it seems like PFE is vulnerable on many fronts.

FL